1. Home
  2. NERV vs IPHA Comparison

NERV vs IPHA Comparison

Compare NERV & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$2.30

Market Cap

166.4M

Sector

Health Care

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.49

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NERV
IPHA
Founded
2007
1999
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
166.4M
165.3M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
NERV
IPHA
Price
$2.30
$1.49
Analyst Decision
Buy
Strong Buy
Analyst Count
3
3
Target Price
★ $10.33
$6.67
AVG Volume (30 Days)
★ 105.4K
33.5K
Earning Date
11-04-2026
09-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $41,175,600.00
N/A
Revenue This Year
N/A
$390.56
Revenue Next Year
N/A
$143.06
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.24
$1.17
52 Week High
$8.80
$2.71

Technical Indicators

Market Signals
Indicator
NERV
IPHA
Relative Strength Index (RSI) 27.35 41.16
Support Level N/A $1.36
Resistance Level $5.69 $1.57
Average True Range (ATR) 0.26 0.08
MACD -0.02 0.02
Stochastic Oscillator 4.83 33.33

Price Performance

Historical Comparison
NERV
IPHA

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: